Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, because that oh-so familiar routine of online calls, meetings, and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to nudge it in a better direction with a cup or three of stimulation. Our choice today is Vermont maple walnut, a seasonal fixation. Meanwhile, we have assembled this list of items of interest for you to peruse. We hope you have a meaningful and productive day. And please do keep in touch. Our settings make it possible to accept telegrams and postcards. …
A pharmaceutical industry trade group argues that a major rules overhaul proposed by the European Commission in April could cause Europe’s share of global research and development to contract by a third to 21% by 2040, translating to $2.15 billion per year in lost investment, Reuters writes. The European Federation of Pharmaceutical Industries and Associations says the commission has not conducted a competitiveness impact assessment and if the new rules become law, they would accelerate the negative innovation trend in the EU and hit small and medium-sized enterprises the hardest.
Meanwhile, Novo Nordisk warned that it will accelerate its U.S. expansion at the expense of the European Union unless Brussels changes the plan to reform industry regulation, The Financial Times adds. Novo chief executive officer Lars Fruergaard Jørgensen said much of the company’s research was now done in Boston and “the journey of expanding in the U.S. would be further accelerated” if the EU implemented its new rules that would cut years of market exclusivity. Jørgensen argued the plan would create a “negative ecosystem.” The industry is concerned by a cut in the number of years of market exclusivity from 10 to eight years.